Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Retained Earnings (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Retained Earnings for 6 consecutive years, with -$501.0 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 2558.06% to -$501.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$501.0 million through Dec 2025, down 2558.06% year-over-year, with the annual reading at -$501.0 million for FY2025, 2558.06% down from the prior year.
  • Retained Earnings for Q4 2025 was -$501.0 million at Mereo BioPharma, down from -$493.7 million in the prior quarter.
  • The five-year high for Retained Earnings was $10.0 million in Q4 2021, with the low at -$501.0 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$216.0 million, with a median of -$18.8 million recorded in 2024.
  • The sharpest move saw Retained Earnings soared 102.44% in 2021, then plummeted 4345.85% in 2025.
  • Over 5 years, Retained Earnings stood at $10.0 million in 2021, then tumbled by 4155.23% to -$404.6 million in 2022, then surged by 95.68% to -$17.5 million in 2023, then decreased by 7.8% to -$18.8 million in 2024, then crashed by 2558.06% to -$501.0 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$501.0 million, -$493.7 million, and -$8.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.